Research Article
Treatment for Nontype 1 Retinopathy of Prematurity by Intravitreal Injection of Antivascular Endothelial Growth Factor Drugs
Table 1
Characteristics of subjects with type 1 and nontype 1 ROP (N = 138).
| | Parametersα | Nontype type I ROP group | Type 1 ROP group | Statistic valueβ | Pβ | | (N = 39) | (N = 99) |
| | GA (week) | 28.5 ± 1.9 | 28.9 ± 2.2 | 1.033 | 0.303 | | BW (kg) | 1.16 ± 0.35 | 1.19 ± 0.37 | 0.504 | 0.615 | | Gender (male, N (%)) | 21 (53.8) | 65 (65.7) | 1.662 | 0.197 | | Hospitalization days in NICU (day) | 56.3 ± 23.2 | 53.6 ± 28.8 | 0.521 | 0.603 | | Time of the first treatment (week) | 39.8 ± 2.7 | 38.1 ± 2.6 | 3.461 | 0.001 | | Follow-up time (week) | 29.5 ± 10.1 | 33.6 ± 15.4 | 1.537 | 0.127 | | Anti-VEGF drugs (N (%)) | | Ranibizumab | 5 (12.8) | 45 (45.5) | 12.896 | 0.000 | | Fusion proteins (conbercept and aflibercept) | 34 (87.2) | 54 (54.5) |
|
|
αGA, gestational age; BW, birth weight. βDifference of gender was analyzed by the χ2 test, and the remaining parameters were tested using the t-test.
|
